RPRX

$66.520.98%-0.66

Nachbörslich: 66.520.00 0.00%

Royalty Pharma Plc (RPRX)

Date: O: H: L: C: Vol:

Schlusskurs vom Vortag:

$67.18

Offen:

$66.97

24-Stunden-Volumen:

2,071,391

Relatives Volumen:

0.66

Marktkapitalisierung:

$29.62B

Einnahmen:

$2.44B

Nettoeinkommen (Verlust:

$1.36B

KGV:

34.84

EPS:

$1.91

Netto-Cashflow:

$574.14M

1W Leistung:

+2.72%

1M Leistung:

+16.38%

6M Leistung:

+34.47%

1Y Leistung:

+77.20%

1-Tages-Spanne:

$66.43$67.10

1-Wochen-Bereich:

$63.49$67.71

52-Wochen-Spanne:

$36.03$67.71

Royalty Pharma Plc Aktie (RPRX) Unternehmensprofil

Firmenname

Royalty Pharma Plc

Sektor

Healthcare

Branche

Biotechnology

Telefon

(212) 883-0200

Adresse

110 EAST 59TH STREET, NEW YORK, NY, USA

Mitarbeiter

100

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

SEC

RPRX-Diskussionen auf X

RPRX vs. VRTX, REGN, MRNA, ARGX, ONC vergleichen

Aktien	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
RPRX Royalty Pharma Plc	$29.62B	$2.54B	$815.00M	$574.14M	$1.91
VRTX Vertex Pharmaceuticals Inc	$140.94B	$12.59B	$4.41B	$3.80B	$16.87
REGN Regeneron Pharmaceuticals Inc	$99.46B	$16.90B	$4.82B	$3.83B	$41.04
MRNA Moderna Inc	$88.17B	$2.23B	-$3.15B	-$1.24B	-$8.15
ARGX Argen X Se Adr	$55.03B	$4.16B	$1.29B	$734.26M	$19.58
ONC Beone Medicines Ltd Adr	$40.86B	$6.13B	$655.71M	$1.33B	$4.48

Royalty Pharma Plc Aktie (RPRX) Hochstufungen & Herabstufungen

Datum	Aktion	Analytiker	Ratingänderung
2026-01-30	Hochstufung	UBS	Neutral → Buy
2025-09-30	Eingeleitet	Goldman	Buy
2025-05-16	Eingeleitet	Morgan Stanley	Overweight
2024-06-03	Herabstufung	UBS	Buy → Neutral
2022-06-14	Resumed	UBS	Buy
2022-05-13	Eingeleitet	Scotiabank	Sector Outperform
2022-04-27	Eingeleitet	Goldman	Buy
2022-04-14	Hochstufung	JP Morgan	Neutral → Overweight
2022-04-06	Resumed	Morgan Stanley	Overweight
2021-10-29	Hochstufung	Citigroup	Neutral → Buy
2021-07-30	Eingeleitet	Tigress Financial	Buy
2020-11-09	Hochstufung	UBS	Neutral → Buy
2020-07-14	Eingeleitet	Evercore ISI	In-line
2020-07-13	Eingeleitet	BofA Securities	Buy
2020-07-13	Eingeleitet	Citigroup	Neutral
2020-07-13	Eingeleitet	Cowen	Outperform
2020-07-13	Eingeleitet	Goldman	Neutral
2020-07-13	Eingeleitet	JP Morgan	Neutral
2020-07-13	Eingeleitet	Morgan Stanley	Equal-Weight
2020-07-13	Eingeleitet	SunTrust	Buy
2020-07-13	Eingeleitet	UBS	Neutral

Finanzdaten der Royalty Pharma Plc-Aktie (RPRX)

Zeitraum	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Enddatum des Zeitraums	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	2,378.19	2,263.58	2,354.55	2,237.22	2,289.46
Research and development USD (M)	452.00	2.00	52.00	177.11	200.08
Operating expenses USD (M)	818.68	971.13	862.40	1,930.15	858.75
Operating income USD (M)	1,559.52	1,292.44	1,492.15	307.07	1,430.72
Income before tax USD (M)	1,324.19	1,330.81	1,700.09	230.06	1,241.20
Income tax expense USD (M)	0.00	0.00	0.00	0.00	0.00
Net income USD (M)	1,324.19	1,330.81	1,700.09	230.06	1,241.20
Basic EPS USD/shares	1.79	1.92	2.54	0.10	1.49
Diluted EPS USD/shares	1.78	1.91	2.53	0.10	1.49
Basic weighted shares shares (M)	429.80	448.19	447.60	437.96	414.79
Diluted weighted shares shares (M)	564.46	594.11	602.90	437.97	414.80

Royalty Pharma Plc-Aktie (RPRX) Insiderhandel

Urist MarshallOct 05 '26
EVP, Research & Investments
Transaktion
Sale
Kosten
$57.10
#Aktien
4,126
Wert ($)
235,595
#Aktien Gesamt
0
Urist MarshallOct 05 '26
Officer
Transaktion
Proposed Sale
Kosten
$57.10
#Aktien
4,126
Wert ($)
235,595
#Aktien Gesamt
0
Urist MarshallSep 28 '26
EVP, Research & Investments
Transaktion
Sale
Kosten
$57.88
#Aktien
4,126
Wert ($)
238,813
#Aktien Gesamt
4,126
Urist MarshallSep 28 '26
Officer
Transaktion
Proposed Sale
Kosten
$57.88
#Aktien
4,126
Wert ($)
238,813
#Aktien Gesamt
0
Hite ChristopherSep 22 '26
EVP & Chairman, Partnering
Transaktion
Sale
Kosten
$58.53
#Aktien
100,000
Wert ($)
5,853,095
#Aktien Gesamt
270,401
SCH Investment Partners LLCSep 22 '26
Officer
Transaktion
Proposed Sale
Kosten
$58.47
#Aktien
100,000
Wert ($)
5,846,972
#Aktien Gesamt
0
SCH Investment Partners LLCAug 18 '26
Officer
Transaktion
Proposed Sale
Kosten
$60.12
#Aktien
100,000
Wert ($)
6,012,000
#Aktien Gesamt
0
Hite ChristopherAug 18 '26
EVP & Chairman, Partnering
Transaktion
Sale
Kosten
$59.97
#Aktien
100,000
Wert ($)
5,997,250
#Aktien Gesamt
370,401
Terrance CoyneAug 13 '26
Officer
Transaktion
Proposed Sale
Kosten
$58.56
#Aktien
11,002
Wert ($)
644,277
#Aktien Gesamt
0
Coyne Terrance P.Aug 13 '26
EVP & CFO
Transaktion
Sale
Kosten
$58.68
#Aktien
11,002
Wert ($)
645,551
#Aktien Gesamt
0

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Urist Marshall	EVP, Research & Investments	Oct 05 '26	Sale	$57.10	4,126	235,595	0
Urist Marshall	Officer	Oct 05 '26	Proposed Sale	$57.10	4,126	235,595	0
Urist Marshall	EVP, Research & Investments	Sep 28 '26	Sale	$57.88	4,126	238,813	4,126
Urist Marshall	Officer	Sep 28 '26	Proposed Sale	$57.88	4,126	238,813	0
Hite Christopher	EVP & Chairman, Partnering	Sep 22 '26	Sale	$58.53	100,000	5,853,095	270,401
SCH Investment Partners LLC	Officer	Sep 22 '26	Proposed Sale	$58.47	100,000	5,846,972	0
SCH Investment Partners LLC	Officer	Aug 18 '26	Proposed Sale	$60.12	100,000	6,012,000	0
Hite Christopher	EVP & Chairman, Partnering	Aug 18 '26	Sale	$59.97	100,000	5,997,250	370,401
Terrance Coyne	Officer	Aug 13 '26	Proposed Sale	$58.56	11,002	644,277	0
Coyne Terrance P.	EVP & CFO	Aug 13 '26	Sale	$58.68	11,002	645,551	0

Royalty Pharma Plc Aktie (RPRX) Neueste Nachrichten

Oct 29, 2026

Should You Buy Royalty Pharma Stock Before Nov. 4? - The Motley Fool

Oct 29, 2026

Guardant Health (GH) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release - Zacks Investment Research

Oct 29, 2026

Oct 25, 2026

Forget Biotech's Binary Bets: This Dividend Stock Collects Royalties on Blockbusters Instead - The Motley Fool

Oct 25, 2026

Oct 16, 2026

Royalty Pharma Announces Fourth-Quarter 2026 Dividend of $0.235 Per Class A Ordinary Share - Quiver Quantitative

Oct 16, 2026

Shareholders are set to get 23.5 cents per share from Royalty Pharma on Dec. 10. - Stock Titan

Oct 16, 2026

Oct 15, 2026

Global femtech market to reach $255.5B by 2035, driven by AI, telehealth, and personalized women's healthcare. - Pluang

Oct 15, 2026

Oct 13, 2026

Should You Invest in the Invesco Biotechnology & Genome ETF (PBE)? - Zacks Investment Research

Oct 13, 2026

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com India

Oct 12, 2026

Royalty Pharma EVP Marshall Urist sells $235,594 in shares - Investing.com

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com Nigeria

Oct 12, 2026

Royalty Pharma EVP Marshall Urist sells $235,594 in shares By Investing.com - Investing.com Nigeria

Oct 12, 2026

Form 4 Royalty Pharma Plc For: 12 October By Investing.com - Investing.com UK

Oct 12, 2026

Oct 08, 2026

Why Royalty Pharma (RPRX) is Poised to Beat Earnings Estimates Again - Zacks Investment Research

Oct 08, 2026

Oct 05, 2026

At $57.10 a share, Royalty Pharma (RPRX) EVP Marshall Urist sells 4,126 shares. - Stock Titan

Oct 05, 2026

Officer Marshall Urist proposes selling 4,126 Royalty Pharma (RPRX) shares. - Stock Titan

Oct 05, 2026

Oct 01, 2026

Royalty Pharma Owns a Piece of 16 Blockbuster Drugs -- Is the Stock a Buy? - The Motley Fool

Oct 01, 2026

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Nigeria

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com South Africa

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares - Investing.com

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com Canada

Sep 30, 2026

Royalty Pharma EVP Marshall Urist sells $238,812 in shares By Investing.com - Investing.com India

Sep 30, 2026

Form 4 Royalty Pharma Plc For: 30 September By Investing.com - Investing.com UK

Sep 30, 2026

A director acquires 642 shares in lieu of a $37,500 retainer at Royalty Pharma (RPRX). - Stock Titan

Sep 30, 2026

4,126 shares sold under a trading plan by Royalty Pharma (RPRX) EVP Marshall Urist. - Stock Titan

Sep 30, 2026

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Nigeria

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com Canada

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com South Africa

Sep 29, 2026

Form 144 Royalty Pharma plc For: 29 September By Investing.com - Investing.com UK

Sep 29, 2026

Sep 28, 2026

Royalty Pharma officer proposes $239K share sale | RPRX SEC Filing - Form 144 - Stock Titan

Sep 28, 2026

Sep 27, 2026

Form 144 Royalty Pharma PLC For: 27 September By Investing.com - Investing.com Nigeria

Sep 27, 2026

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com India

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com Canada

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Nigeria

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares - Investing.com

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com Canada

Sep 25, 2026

Form 4 Royalty Pharma Plc For: 25 September By Investing.com - Investing.com UK

Sep 25, 2026

Royalty Pharma EVP Christopher Hite sells $5.85m in shares By Investing.com - Investing.com UK

Sep 25, 2026

Sep 23, 2026